VasoGenix Pharmaceuticals Elects Pharma Industry Veteran Dr. Judith A. Hemberger to Board of Directors

Contact: Ronald C. Trahan, APR, Ronald Trahan Associates Inc., (508) 359-4005, x108

VasoGenix Pharmaceuticals elects pharma industry veteran
Dr. Judith A. Hemberger to its board of directors

LENEXA, Kan., March 23, 2009-VasoGenix Pharmaceuticals announced today that Judith A. Hemberger, Ph.D., has been elected to its board of directors.

Dr. Hemberger is currently a director of Zymogenetics, Chroma, Atani Ltd., and Zosano Pharma. Previously, she was a director at Marion Merrell Dow, NeXstar Pharmaceuticals, Pharmion Corp., Perrigo Corp., Myogen and Novacca. Her corporate executive experiences include: interim CEO at Zosano; Co-Founder, Executive Vice President and Chief Operating Officer of Pharmion; Head of Business Development at Avax Technologies; and numerous operational roles at Marion Merrell Dow and Hoechst Marion Roussel, where her final position was Senior Vice President, Global Regulatory Affairs.

"Dr. Hemberger is a seasoned pharmaceutical executive who will be important to the growth of VasoGenix Pharmaceuticals as we develop our new CGRP (calcitonin gene related peptide) agonist analogs to treat heart failure," said G. Lee Southard, Ph.D., Chairman and CEO of VasoGenix Pharmaceuticals. "Her tremendous experience in drug development and finance will be of great help in guiding VasoGenix into the future. Particularly in this difficult economic time, VasoGenix is very fortunate to have Judy Hemberger join its board of directors."

"VasoGenix's lead h-α-CGRP analog is at a very exciting stage of development," added Dr Hemberger. "With the significant body of documented research and safety profile for this class of drug, there is the potential for an expedited development program. This molecule offers significant advantages to patients over current treatments, and its positive potential impact on cost to the public health system for the treatment of heart failure is significant."

VasoGenix Pharmaceuticals is a privately held, emerging biopharmaceutical company focused on developing cardiovascular drugs. The Company is focused initially on positioning its compound related to ‘CGRP' (calcitonin gene related peptide) as a front-line treatment for heart failure.

Statements contained in this press release, which are not historical facts, are forward-looking statements, as the term is defined in the Private Securities Litigation Reform Act of 1995. You can identify these forward-looking statements by the use of words such as, "expects," "plans," "estimates," "projects," "promises," "intends," "believes," and similar expressions that do not relate to historical matters. Such forward-looking statements are subject to risks and uncertainties which can cause actual results to differ materially from those currently anticipated, due to a number of factors, which include, but are not limited to, to identify strategic partners or, if identified, the inability to enter into an acceptable agreement with such strategic partners and successfully concluding the development and regulatory processes. All forward-looking statements in this press release are made as of today, based upon information known to management as of the date hereof. VasoGenix assumes no obligation to update or revise any of its forward-looking statements even if experience or future changes show that indicated results or events will not be realized.

# # # # #